Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 23;8(1):e000842. doi: 10.1136/jitc-2020-000842

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Increased serum IL-6 and CRP levels are associated with reduced survival after nivolumab or ipilimumab treatment in Checkmate-064. Kaplan-Meier survival curves were calculated for patients stratified according to the median serum levels at week 13 (after first treatment) of (A) IL-6 in patients receiving sequential nivolumab then ipilimumab (cohort A); (B) IL-6 in patients receiving sequential ipilimumab then nivolumab (cohort B); (C) CRP in cohort A; and (D) CRP in cohort B. Median IL-6, 13.6 pg/mL. Median CRP, 15.8 ug/mL. HR adjusted for ECOG, BRAF, M stage, baseline LDH, and melanoma subtype. Patients below the median or LLOQ are represented by blue lines and those above by red lines. CRP, C-reactive protein; IL, interleukin; LLOQ, lower limit of quantification; M, metastases; OS, overall survival.